ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC)

Clinical trials for ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC) trials appear

Sign up with your email to follow new studies for ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Experimental cancer pill shows promise in early trial

Disease control Terminated

This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when g…

Matched conditions: ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC)

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated May 14, 2026 12:04 UTC

ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC)

Get alerted when new ADVANCED EGFR MUTANT NON SMALL CELL LUNGCANCER (NSCLC) trials appear

Experimental cancer pill shows promise in early trial